Literature DB >> 8794355

Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients.

B Rehermann1, K M Chang, J McHutchinson, R Kokka, M Houghton, C M Rice, F V Chisari.   

Abstract

Cytotoxic T lymphocytes (CTL) are thought to control hepatitis B virus (HBV) infection, since they are readily detectable in patients who clear the virus whereas they are hard to detect during chronic HBV infection. In chronic hepatitis C virus (HCV) infection, however, the virus persists in the face of a CTL response. Indeed, most infected patients respond to one or more HCV-1 (genotype 1a)-derived CTL epitopes in the core, NS3, and NS4 proteins, and the CTL response is equally strong in patients infected by different HCV genotypes, suggesting broad cross-reactivity. To examine the effect of the HCV-specific CTL response in patients with chronic hepatitis C on viral load and disease activity, we quantitated the strength of the multispecific CTL response against 10 independent epitopes within the HCV polyprotein. We could not detect a linear correlation between the CTL response and viral load or disease activity in these patients. However, the CTL response was stronger in the subgroup of patients whose HCV RNA was below the detection threshold of the HCV branched- chain DNA assay than in branched-chain-DNA-positive patients. These results suggest that the HCV-specific CTL response may be able to control viral load to some extent in chronically infected patients, and they indicate that prospective studies in acutely infected patients who successfully clear HCV should be performed to more precisely define the relationship between CTL responsiveness, viral clearance, and disease severity in this infection.

Entities:  

Mesh:

Year:  1996        PMID: 8794355      PMCID: PMC190761     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

1.  HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen.

Authors:  A Bertoletti; C Ferrari; F Fiaccadori; A Penna; R Margolskee; H J Schlicht; P Fowler; S Guilhot; F V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

2.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

3.  Antigen presentation by Toxoplasma gondii-infected cells to CD4+ proliferative T cells and CD8+ cytotoxic cells.

Authors:  A Yano; F Aosai; M Ohta; H Hasekura; K Sugane; S Hayashi
Journal:  J Parasitol       Date:  1989-06       Impact factor: 1.276

4.  Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection.

Authors:  M J Alter; S C Hadler; F N Judson; A Mares; W J Alexander; P Y Hu; J K Miller; L A Moyer; H A Fields; D W Bradley
Journal:  JAMA       Date:  1990-11-07       Impact factor: 56.272

5.  Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis.

Authors:  M J Koziel; D Dudley; J T Wong; J Dienstag; M Houghton; R Ralston; B D Walker
Journal:  J Immunol       Date:  1992-11-15       Impact factor: 5.422

6.  Clonal expansion and functional analysis of virus-specific T lymphocytes from cerebrospinal fluid in measles encephalitis.

Authors:  B Fleischer; H W Kreth
Journal:  Hum Immunol       Date:  1983-08       Impact factor: 2.850

7.  Human cytomegalovirus-specific cytotoxic T lymphocytes: requirements for in vitro generation and specificity.

Authors:  L K Borysiewicz; S Morris; J D Page; J G Sissons
Journal:  Eur J Immunol       Date:  1983-10       Impact factor: 5.532

8.  Hepatitis B virus genes and their expression in E. coli.

Authors:  M Pasek; T Goto; W Gilbert; B Zink; H Schaller; P MacKay; G Leadbetter; K Murray
Journal:  Nature       Date:  1979-12-06       Impact factor: 49.962

9.  CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1.

Authors:  M Shirai; T Arichi; M Nishioka; T Nomura; K Ikeda; K Kawanishi; V H Engelhard; S M Feinstone; J A Berzofsky
Journal:  J Immunol       Date:  1995-03-15       Impact factor: 5.422

10.  Analysis of a new hepatitis C virus type and its phylogenetic relationship to existing variants.

Authors:  S W Chan; F McOmish; E C Holmes; B Dow; J F Peutherer; E Follett; P L Yap; P Simmonds
Journal:  J Gen Virol       Date:  1992-05       Impact factor: 3.891

View more
  64 in total

Review 1.  Immunopathogenesis of viral hepatitis.

Authors:  M U Mondelli
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

2.  Enhancing B- and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer.

Authors:  S Zucchelli; S Capone; E Fattori; A Folgori; A Di Marco; D Casimiro; A J Simon; R Laufer; N La Monica; R Cortese; A Nicosia
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Exposure to low infective doses of HCV induces cellular immune responses without consistently detectable viremia or seroconversion in chimpanzees.

Authors:  Mohamed Tarek Shata; Nancy Tricoche; Marion Perkus; Darley Tom; Betsy Brotman; Patricia McCormack; Wolfram Pfahler; Dong-Hun Lee; Leslie H Tobler; Michael Busch; Alfred M Prince
Journal:  Virology       Date:  2003-09-30       Impact factor: 3.616

Review 4.  Acute hepatitis C virus infection: a chronic problem.

Authors:  Jason T Blackard; M Tarek Shata; Norah J Shire; Kenneth E Sherman
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

5.  Detection of diverse hepatitis C virus (HCV)-specific cytotoxic T lymphocytes in peripheral blood of infected persons by screening for responses to all translated proteins of HCV.

Authors:  D K Wong; D D Dudley; P B Dohrenwend; G M Lauer; R T Chung; D L Thomas; B D Walker
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

6.  Specific gut commensal flora locally alters T cell tuning to endogenous ligands.

Authors:  Pascal Chappert; Nicolas Bouladoux; Shruti Naik; Ronald H Schwartz
Journal:  Immunity       Date:  2013-06-27       Impact factor: 31.745

7.  Characterization of the peptide-binding specificity of Mamu-A*11 results in the identification of SIV-derived epitopes and interspecies cross-reactivity.

Authors:  Alessandro Sette; John Sidney; Huynh-Hoa Bui; Marie-France del Guercio; Jeff Alexander; John Loffredo; David I Watkins; Bianca R Mothé
Journal:  Immunogenetics       Date:  2005-03-04       Impact factor: 2.846

8.  Hepatitis C virus mutation affects proteasomal epitope processing.

Authors:  Ulrike Seifert; Heike Liermann; Vito Racanelli; Anne Halenius; Manfred Wiese; Heiner Wedemeyer; Thomas Ruppert; Kay Rispeter; Peter Henklein; Alice Sijts; Hartmut Hengel; Peter-M Kloetzel; Barbara Rehermann
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

9.  Genomic analysis of the host response to hepatitis B virus infection.

Authors:  Stefan Wieland; Robert Thimme; Robert H Purcell; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-20       Impact factor: 11.205

10.  The size of the viral inoculum contributes to the outcome of hepatitis B virus infection.

Authors:  Shinichi Asabe; Stefan F Wieland; Pratip K Chattopadhyay; Mario Roederer; Ronald E Engle; Robert H Purcell; Francis V Chisari
Journal:  J Virol       Date:  2009-07-22       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.